scispace - formally typeset
Search or ask a question
Author

Christian C. Abnet

Bio: Christian C. Abnet is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Population & Cancer. The author has an hindex of 86, co-authored 413 publications receiving 29165 citations. Previous affiliations of Christian C. Abnet include Washington University in St. Louis & United States Department of Health and Human Services.


Papers
More filters
Journal ArticleDOI
Evan Bolyen1, Jai Ram Rideout1, Matthew R. Dillon1, Nicholas A. Bokulich1, Christian C. Abnet2, Gabriel A. Al-Ghalith3, Harriet Alexander4, Harriet Alexander5, Eric J. Alm6, Manimozhiyan Arumugam7, Francesco Asnicar8, Yang Bai9, Jordan E. Bisanz10, Kyle Bittinger11, Asker Daniel Brejnrod7, Colin J. Brislawn12, C. Titus Brown5, Benjamin J. Callahan13, Andrés Mauricio Caraballo-Rodríguez14, John Chase1, Emily K. Cope1, Ricardo Silva14, Christian Diener15, Pieter C. Dorrestein14, Gavin M. Douglas16, Daniel M. Durall17, Claire Duvallet6, Christian F. Edwardson, Madeleine Ernst14, Madeleine Ernst18, Mehrbod Estaki17, Jennifer Fouquier19, Julia M. Gauglitz14, Sean M. Gibbons15, Sean M. Gibbons20, Deanna L. Gibson17, Antonio Gonzalez14, Kestrel Gorlick1, Jiarong Guo21, Benjamin Hillmann3, Susan Holmes22, Hannes Holste14, Curtis Huttenhower23, Curtis Huttenhower24, Gavin A. Huttley25, Stefan Janssen26, Alan K. Jarmusch14, Lingjing Jiang14, Benjamin D. Kaehler27, Benjamin D. Kaehler25, Kyo Bin Kang14, Kyo Bin Kang28, Christopher R. Keefe1, Paul Keim1, Scott T. Kelley29, Dan Knights3, Irina Koester14, Tomasz Kosciolek14, Jorden Kreps1, Morgan G. I. Langille16, Joslynn S. Lee30, Ruth E. Ley31, Ruth E. Ley32, Yong-Xin Liu, Erikka Loftfield2, Catherine A. Lozupone19, Massoud Maher14, Clarisse Marotz14, Bryan D Martin20, Daniel McDonald14, Lauren J. McIver24, Lauren J. McIver23, Alexey V. Melnik14, Jessica L. Metcalf33, Sydney C. Morgan17, Jamie Morton14, Ahmad Turan Naimey1, Jose A. Navas-Molina34, Jose A. Navas-Molina14, Louis-Félix Nothias14, Stephanie B. Orchanian, Talima Pearson1, Samuel L. Peoples20, Samuel L. Peoples35, Daniel Petras14, Mary L. Preuss36, Elmar Pruesse19, Lasse Buur Rasmussen7, Adam R. Rivers37, Michael S. Robeson38, Patrick Rosenthal36, Nicola Segata8, Michael Shaffer19, Arron Shiffer1, Rashmi Sinha2, Se Jin Song14, John R. Spear39, Austin D. Swafford, Luke R. Thompson40, Luke R. Thompson41, Pedro J. Torres29, Pauline Trinh20, Anupriya Tripathi14, Peter J. Turnbaugh10, Sabah Ul-Hasan42, Justin J. J. van der Hooft43, Fernando Vargas, Yoshiki Vázquez-Baeza14, Emily Vogtmann2, Max von Hippel44, William A. Walters31, Yunhu Wan2, Mingxun Wang14, Jonathan Warren45, Kyle C. Weber37, Kyle C. Weber46, Charles H. D. Williamson1, Amy D. Willis20, Zhenjiang Zech Xu14, Jesse R. Zaneveld20, Yilong Zhang47, Qiyun Zhu14, Rob Knight14, J. Gregory Caporaso1 
TL;DR: QIIME 2 development was primarily funded by NSF Awards 1565100 to J.G.C. and R.K.P. and partial support was also provided by the following: grants NIH U54CA143925 and U54MD012388.
Abstract: QIIME 2 development was primarily funded by NSF Awards 1565100 to J.G.C. and 1565057 to R.K. Partial support was also provided by the following: grants NIH U54CA143925 (J.G.C. and T.P.) and U54MD012388 (J.G.C. and T.P.); grants from the Alfred P. Sloan Foundation (J.G.C. and R.K.); ERCSTG project MetaPG (N.S.); the Strategic Priority Research Program of the Chinese Academy of Sciences QYZDB-SSW-SMC021 (Y.B.); the Australian National Health and Medical Research Council APP1085372 (G.A.H., J.G.C., Von Bing Yap and R.K.); the Natural Sciences and Engineering Research Council (NSERC) to D.L.G.; and the State of Arizona Technology and Research Initiative Fund (TRIF), administered by the Arizona Board of Regents, through Northern Arizona University. All NCI coauthors were supported by the Intramural Research Program of the National Cancer Institute. S.M.G. and C. Diener were supported by the Washington Research Foundation Distinguished Investigator Award.

8,821 citations

Posted ContentDOI
Evan Bolyen1, Jai Ram Rideout1, Matthew R. Dillon1, Nicholas A. Bokulich1, Christian C. Abnet, Gabriel A. Al-Ghalith2, Harriet Alexander3, Harriet Alexander4, Eric J. Alm5, Manimozhiyan Arumugam6, Francesco Asnicar7, Yang Bai8, Jordan E. Bisanz9, Kyle Bittinger10, Asker Daniel Brejnrod6, Colin J. Brislawn11, C. Titus Brown3, Benjamin J. Callahan12, Andrés Mauricio Caraballo-Rodríguez13, John Chase1, Emily K. Cope1, Ricardo Silva13, Pieter C. Dorrestein13, Gavin M. Douglas14, Daniel M. Durall15, Claire Duvallet5, Christian F. Edwardson16, Madeleine Ernst13, Mehrbod Estaki15, Jennifer Fouquier17, Julia M. Gauglitz13, Deanna L. Gibson15, Antonio Gonzalez18, Kestrel Gorlick1, Jiarong Guo19, Benjamin Hillmann2, Susan Holmes20, Hannes Holste18, Curtis Huttenhower21, Curtis Huttenhower22, Gavin A. Huttley23, Stefan Janssen24, Alan K. Jarmusch13, Lingjing Jiang18, Benjamin D. Kaehler23, Kyo Bin Kang13, Kyo Bin Kang25, Christopher R. Keefe1, Paul Keim1, Scott T. Kelley26, Dan Knights2, Irina Koester13, Irina Koester18, Tomasz Kosciolek18, Jorden Kreps1, Morgan G. I. Langille14, Joslynn S. Lee27, Ruth E. Ley28, Ruth E. Ley29, Yong-Xin Liu8, Erikka Loftfield, Catherine A. Lozupone17, Massoud Maher18, Clarisse Marotz18, Bryan D Martin30, Daniel McDonald18, Lauren J. McIver22, Lauren J. McIver21, Alexey V. Melnik13, Jessica L. Metcalf31, Sydney C. Morgan15, Jamie Morton18, Ahmad Turan Naimey1, Jose A. Navas-Molina32, Jose A. Navas-Molina18, Louis-Félix Nothias13, Stephanie B. Orchanian18, Talima Pearson1, Samuel L. Peoples33, Samuel L. Peoples30, Daniel Petras13, Mary L. Preuss34, Elmar Pruesse17, Lasse Buur Rasmussen6, Adam R. Rivers35, Ii Michael S Robeson36, Patrick Rosenthal34, Nicola Segata7, Michael Shaffer17, Arron Shiffer1, Rashmi Sinha, Se Jin Song18, John R. Spear37, Austin D. Swafford18, Luke R. Thompson38, Luke R. Thompson39, Pedro J. Torres26, Pauline Trinh30, Anupriya Tripathi13, Anupriya Tripathi18, Peter J. Turnbaugh9, Sabah Ul-Hasan40, Justin J. J. van der Hooft41, Fernando Vargas18, Yoshiki Vázquez-Baeza18, Emily Vogtmann, Max von Hippel42, William A. Walters28, Yunhu Wan, Mingxun Wang13, Jonathan Warren43, Kyle C. Weber35, Kyle C. Weber44, Chase Hd Williamson1, Amy D. Willis30, Zhenjiang Zech Xu18, Jesse R. Zaneveld30, Yilong Zhang45, Rob Knight18, J. Gregory Caporaso1 
24 Oct 2018-PeerJ
TL;DR: QIIME 2 provides new features that will drive the next generation of microbiome research, including interactive spatial and temporal analysis and visualization tools, support for metabolomics and shotgun metagenomics analysis, and automated data provenance tracking to ensure reproducible, transparent microbiome data science.
Abstract: We present QIIME 2, an open-source microbiome data science platform accessible to users spanning the microbiome research ecosystem, from scientists and engineers to clinicians and policy makers. QIIME 2 provides new features that will drive the next generation of microbiome research. These include interactive spatial and temporal analysis and visualization tools, support for metabolomics and shotgun metagenomics analysis, and automated data provenance tracking to ensure reproducible, transparent microbiome data science.

875 citations

Journal ArticleDOI
17 Aug 2011-JAMA
TL;DR: Compared with a pooled estimate of US data from cohorts initiated between 1963 and 1987, relative risks for smoking in the more recent NIH-AARP Diet and Health Study cohort were higher, with PARs for women comparable with those for men.
Abstract: =0.0%). The PAR for ever smoking in our study was 0.50 (95% CI, 0.45-0.54) in men and 0.52 (95% CI, 0.45-0.59) in women. Conclusion Compared with a pooled estimate of US data from cohorts initiated between 1963 and 1987, relative risks for smoking in the more recent NIH-AARP Diet and Health Study cohort were higher, with PARs for women comparable with those for men.

758 citations

Journal ArticleDOI
TL;DR: Esophageal squamous cell carcinoma has been understudied, but growing infrastructure in more high-incidence countries will allow rapid progress in understanding, and large genome-wide association studies have been conducted with ethnic Chinese subjects only; more studies are called for in the rest of Asia and Africa.

713 citations

Journal ArticleDOI
TL;DR: There was a uniform decrease in gastric cancer incidence but an increasing incidence of colorectal cancer in formerly low-incidence regions over the studied time period, and slight increases in incidence of liver and pancreatic cancer in some high-income regions.

670 citations


Cited by
More filters
Journal ArticleDOI
TL;DR: A status report on the global burden of cancer worldwide using the GLOBOCAN 2018 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer, with a focus on geographic variability across 20 world regions.
Abstract: This article provides a status report on the global burden of cancer worldwide using the GLOBOCAN 2018 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer, with a focus on geographic variability across 20 world regions There will be an estimated 181 million new cancer cases (170 million excluding nonmelanoma skin cancer) and 96 million cancer deaths (95 million excluding nonmelanoma skin cancer) in 2018 In both sexes combined, lung cancer is the most commonly diagnosed cancer (116% of the total cases) and the leading cause of cancer death (184% of the total cancer deaths), closely followed by female breast cancer (116%), prostate cancer (71%), and colorectal cancer (61%) for incidence and colorectal cancer (92%), stomach cancer (82%), and liver cancer (82%) for mortality Lung cancer is the most frequent cancer and the leading cause of cancer death among males, followed by prostate and colorectal cancer (for incidence) and liver and stomach cancer (for mortality) Among females, breast cancer is the most commonly diagnosed cancer and the leading cause of cancer death, followed by colorectal and lung cancer (for incidence), and vice versa (for mortality); cervical cancer ranks fourth for both incidence and mortality The most frequently diagnosed cancer and the leading cause of cancer death, however, substantially vary across countries and within each country depending on the degree of economic development and associated social and life style factors It is noteworthy that high-quality cancer registry data, the basis for planning and implementing evidence-based cancer control programs, are not available in most low- and middle-income countries The Global Initiative for Cancer Registry Development is an international partnership that supports better estimation, as well as the collection and use of local data, to prioritize and evaluate national cancer control efforts CA: A Cancer Journal for Clinicians 2018;0:1-31 © 2018 American Cancer Society

58,675 citations

Journal ArticleDOI
TL;DR: A substantial proportion of the worldwide burden of cancer could be prevented through the application of existing cancer control knowledge and by implementing programs for tobacco control, vaccination, and early detection and treatment, as well as public health campaigns promoting physical activity and a healthier dietary intake.
Abstract: The global burden of cancer continues to increase largely because of the aging and growth of the world population alongside an increasing adoption of cancer-causing behaviors, particularly smoking, in economically developing countries. Based on the GLOBOCAN 2008 estimates, about 12.7 million cancer cases and 7.6 million cancer deaths are estimated to have occurred in 2008; of these, 56% of the cases and 64% of the deaths occurred in the economically developing world. Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death among females, accounting for 23% of the total cancer cases and 14% of the cancer deaths. Lung cancer is the leading cancer site in males, comprising 17% of the total new cancer cases and 23% of the total cancer deaths. Breast cancer is now also the leading cause of cancer death among females in economically developing countries, a shift from the previous decade during which the most common cause of cancer death was cervical cancer. Further, the mortality burden for lung cancer among females in developing countries is as high as the burden for cervical cancer, with each accounting for 11% of the total female cancer deaths. Although overall cancer incidence rates in the developing world are half those seen in the developed world in both sexes, the overall cancer mortality rates are generally similar. Cancer survival tends to be poorer in developing countries, most likely because of a combination of a late stage at diagnosis and limited access to timely and standard treatment. A substantial proportion of the worldwide burden of cancer could be prevented through the application of existing cancer control knowledge and by implementing programs for tobacco control, vaccination (for liver and cervical cancers), and early detection and treatment, as well as public health campaigns promoting physical activity and a healthier dietary intake. Clinicians, public health professionals, and policy makers can play an active role in accelerating the application of such interventions globally.

52,293 citations

Journal ArticleDOI
TL;DR: The GLOBOCAN 2020 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer (IARC) as mentioned in this paper show that female breast cancer has surpassed lung cancer as the most commonly diagnosed cancer, with an estimated 2.3 million new cases (11.7%), followed by lung cancer, colorectal (11 4.4%), liver (8.3%), stomach (7.7%) and female breast (6.9%), and cervical cancer (5.6%) cancers.
Abstract: This article provides an update on the global cancer burden using the GLOBOCAN 2020 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer. Worldwide, an estimated 19.3 million new cancer cases (18.1 million excluding nonmelanoma skin cancer) and almost 10.0 million cancer deaths (9.9 million excluding nonmelanoma skin cancer) occurred in 2020. Female breast cancer has surpassed lung cancer as the most commonly diagnosed cancer, with an estimated 2.3 million new cases (11.7%), followed by lung (11.4%), colorectal (10.0 %), prostate (7.3%), and stomach (5.6%) cancers. Lung cancer remained the leading cause of cancer death, with an estimated 1.8 million deaths (18%), followed by colorectal (9.4%), liver (8.3%), stomach (7.7%), and female breast (6.9%) cancers. Overall incidence was from 2-fold to 3-fold higher in transitioned versus transitioning countries for both sexes, whereas mortality varied <2-fold for men and little for women. Death rates for female breast and cervical cancers, however, were considerably higher in transitioning versus transitioned countries (15.0 vs 12.8 per 100,000 and 12.4 vs 5.2 per 100,000, respectively). The global cancer burden is expected to be 28.4 million cases in 2040, a 47% rise from 2020, with a larger increase in transitioning (64% to 95%) versus transitioned (32% to 56%) countries due to demographic changes, although this may be further exacerbated by increasing risk factors associated with globalization and a growing economy. Efforts to build a sustainable infrastructure for the dissemination of cancer prevention measures and provision of cancer care in transitioning countries is critical for global cancer control.

35,190 citations

Journal ArticleDOI
TL;DR: A substantial portion of cancer cases and deaths could be prevented by broadly applying effective prevention measures, such as tobacco control, vaccination, and the use of early detection tests.
Abstract: Cancer constitutes an enormous burden on society in more and less economically developed countries alike. The occurrence of cancer is increasing because of the growth and aging of the population, as well as an increasing prevalence of established risk factors such as smoking, overweight, physical inactivity, and changing reproductive patterns associated with urbanization and economic development. Based on GLOBOCAN estimates, about 14.1 million new cancer cases and 8.2 million deaths occurred in 2012 worldwide. Over the years, the burden has shifted to less developed countries, which currently account for about 57% of cases and 65% of cancer deaths worldwide. Lung cancer is the leading cause of cancer death among males in both more and less developed countries, and has surpassed breast cancer as the leading cause of cancer death among females in more developed countries; breast cancer remains the leading cause of cancer death among females in less developed countries. Other leading causes of cancer death in more developed countries include colorectal cancer among males and females and prostate cancer among males. In less developed countries, liver and stomach cancer among males and cervical cancer among females are also leading causes of cancer death. Although incidence rates for all cancers combined are nearly twice as high in more developed than in less developed countries in both males and females, mortality rates are only 8% to 15% higher in more developed countries. This disparity reflects regional differences in the mix of cancers, which is affected by risk factors and detection practices, and/or the availability of treatment. Risk factors associated with the leading causes of cancer death include tobacco use (lung, colorectal, stomach, and liver cancer), overweight/obesity and physical inactivity (breast and colorectal cancer), and infection (liver, stomach, and cervical cancer). A substantial portion of cancer cases and deaths could be prevented by broadly applying effective prevention measures, such as tobacco control, vaccination, and the use of early detection tests.

23,203 citations

Journal ArticleDOI
TL;DR: Many of the estimated cancer cases and deaths can be prevented through reducing the prevalence of risk factors, while increasing the effectiveness of clinical care delivery, particularly for those living in rural areas and in disadvantaged populations.
Abstract: With increasing incidence and mortality, cancer is the leading cause of death in China and is a major public health problem. Because of China's massive population (1.37 billion), previous national incidence and mortality estimates have been limited to small samples of the population using data from the 1990s or based on a specific year. With high-quality data from an additional number of population-based registries now available through the National Central Cancer Registry of China, the authors analyzed data from 72 local, population-based cancer registries (2009-2011), representing 6.5% of the population, to estimate the number of new cases and cancer deaths for 2015. Data from 22 registries were used for trend analyses (2000-2011). The results indicated that an estimated 4292,000 new cancer cases and 2814,000 cancer deaths would occur in China in 2015, with lung cancer being the most common incident cancer and the leading cause of cancer death. Stomach, esophageal, and liver cancers were also commonly diagnosed and were identified as leading causes of cancer death. Residents of rural areas had significantly higher age-standardized (Segi population) incidence and mortality rates for all cancers combined than urban residents (213.6 per 100,000 vs 191.5 per 100,000 for incidence; 149.0 per 100,000 vs 109.5 per 100,000 for mortality, respectively). For all cancers combined, the incidence rates were stable during 2000 through 2011 for males (+0.2% per year; P = .1), whereas they increased significantly (+2.2% per year; P < .05) among females. In contrast, the mortality rates since 2006 have decreased significantly for both males (-1.4% per year; P < .05) and females (-1.1% per year; P < .05). Many of the estimated cancer cases and deaths can be prevented through reducing the prevalence of risk factors, while increasing the effectiveness of clinical care delivery, particularly for those living in rural areas and in disadvantaged populations.

13,073 citations